Amicus Therapeutics, Inc. (FOLD): Price and Financial Metrics
FOLD Price/Volume Stats
| Current price | $11.03 | 52-week high | $14.10 |
| Prev. close | $12.16 | 52-week low | $9.10 |
| Day low | $10.94 | Volume | 3,598,100 |
| Day high | $12.16 | Avg. volume | 2,383,865 |
| 50-day MA | $12.89 | Dividend yield | N/A |
| 200-day MA | $12.34 | Market Cap | 3.17B |
FOLD Stock Price Chart Interactive Chart >
FOLD POWR Grades
- FOLD scores best on the Growth dimension, with a Growth rank ahead of 95.36% of US stocks.
- FOLD's strongest trending metric is Stability; it's been moving down over the last 177 days.
- FOLD ranks lowest in Sentiment; there it ranks in the 6th percentile.
FOLD Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for FOLD is 3.14 -- better than 82.95% of US stocks.
- FOLD's price/sales ratio is 10.04; that's higher than the P/S ratio of 90.46% of US stocks.
- The volatility of AMICUS THERAPEUTICS INC's share price is greater than that of merely 14.52% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to FOLD, based on their financial statements, market capitalization, and price volatility, are QUIK, KIND, LITE, IVAC, and ORGN.
- FOLD's SEC filings can be seen here. And to visit AMICUS THERAPEUTICS INC's official web site, go to www.amicusrx.com.
FOLD Valuation Summary
- FOLD's EV/EBIT ratio is -25.4; this is 318.97% lower than that of the median Healthcare stock.
- Over the past 199 months, FOLD's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for FOLD.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FOLD | 2023-09-22 | 10.0 | 31.5 | -19.0 | -25.4 |
| FOLD | 2023-09-21 | 10.0 | 31.4 | -18.9 | -25.3 |
| FOLD | 2023-09-20 | 10.1 | 31.7 | -19.1 | -25.5 |
| FOLD | 2023-09-19 | 10.6 | 33.2 | -20.0 | -26.6 |
| FOLD | 2023-09-18 | 10.5 | 33.1 | -20.0 | -26.6 |
| FOLD | 2023-09-15 | 10.7 | 33.7 | -20.3 | -27.0 |
FOLD Growth Metrics
- Its 2 year price growth rate is now at -42%.
- Its 4 year net cashflow from operations growth rate is now at -80.01%.
- The 5 year price growth rate now stands at 74.74%.
The table below shows FOLD's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 323.291 | -156.317 | -263.98 |
| 2022-06-30 | 321.145 | -168.391 | -280.988 |
| 2022-03-31 | 317.827 | -188.452 | -270.056 |
| 2021-12-31 | 305.514 | -202.491 | -250.46 |
| 2021-09-30 | 293.931 | -181.799 | -238.584 |
| 2021-06-30 | 281.823 | -200.107 | -252.301 |
FOLD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- FOLD has a Quality Grade of C, ranking ahead of 63.39% of graded US stocks.
- FOLD's asset turnover comes in at 0.333 -- ranking 138th of 680 Pharmaceutical Products stocks.
- RDUS, CLVS, and NSTG are the stocks whose asset turnover ratios are most correlated with FOLD.
The table below shows FOLD's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.333 | 0.884 | -0.273 |
| 2021-03-31 | 0.323 | 0.884 | -0.312 |
| 2020-12-31 | 0.323 | 0.881 | -0.383 |
| 2020-09-30 | 0.308 | 0.884 | -0.458 |
| 2020-06-30 | 0.286 | 0.886 | -0.501 |
| 2020-03-31 | 0.246 | 0.883 | -0.524 |
FOLD Price Target
For more insight on analysts targets of FOLD, see our FOLD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $16.90 | Average Broker Recommendation | 1.64 (Moderate Buy) |
Amicus Therapeutics, Inc. (FOLD) Company Bio
Amicus Therapeutics is developing treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.
Latest FOLD News From Around the Web
Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.
Amicus (FOLD) Gets FDA Approval for Pompe Disease DrugAmicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease. |
UPDATE 1-US FDA approves Amicus Therapeutics' muscle disorder treatmentAmicus Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a muscle disorder called Pompe disease. The health regulator last October extended its review for a second time following delays in inspections caused by pandemic-related travel restrictions. The therapy is indicated for use in adults living with late-onset Pompe disease and those without an improvement on their current enzyme replacement therapy, the company said. |
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe DiseasePombiliti + Opfolda Logo Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (migl |
Amicus Therapeutics Stock Reaches 80+ Relative Strength BenchmarkAmicus Therapeutics just cleared that benchmark with an upgrade from 77 to 82. Amicus Therapeutics is trying to complete a consolidation with a 14.10 buy point. Amicus Therapeutics earns the No. 39 rank among its peers in the Medical-Biomed/Biotech industry group. |
Zacks.com featured highlights include Amicus Therapeutics, Genius Sports and ViadAmicus Therapeutics, Genius Sports and Viad are part of the Zacks Screen of the Week article. |
FOLD Price Returns
| 1-mo | -14.63% |
| 3-mo | N/A |
| 6-mo | -0.27% |
| 1-year | 5.65% |
| 3-year | -18.11% |
| 5-year | -15.80% |
| YTD | -9.66% |
| 2022 | 5.71% |
| 2021 | -49.98% |
| 2020 | 137.06% |
| 2019 | 1.67% |
| 2018 | -33.43% |
Continue Researching FOLD
Here are a few links from around the web to help you further your research on Amicus Therapeutics Inc's stock as an investment opportunity:Amicus Therapeutics Inc (FOLD) Stock Price | Nasdaq
Amicus Therapeutics Inc (FOLD) Stock Quote, History and News - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...